MM-VAC

1.0 ml of the vaccine contains

Vial with the lyophilized component MXT:

Active substances:
Poxvirus myxomatosae attenuatum 10^4.6 – 10^7.6 CCID₅₀.

Excipients:
freeze-drying medium.

Vial with the liquid component RHD:

Active substances:
Calicivirus septicemiae haemorrhagicae cuniculi inactivatum inducing antibodies of NLT 32 HIU₅₀*.
*HIU₅₀: amount of antibodies determined in laboratory animals, which corresponds with high protection of animals P = 0.99.

Adjuvants:
oil emulsion NMT 0.3 ml,
saponin NMT 0.25 mg.

Excipients:
thiomersal NMT 0.2 mg,
diluting medium for virus up to 1.0 ml.

Indications

The MM-VAC vaccine is designed for an active immunization of rabbits against myxomatosis and rabbit haemorrhagic disease.

Contraindications

Do not use in cases of an organ and feverish disease. The vaccine must not be used in case the animals suffer from myxomatosis or rabbit haemorrhagic disease.

Dosage and method of administration

Immunization dose is applied intradermally (i.d.) by the needleless applicator. On administration, the both auricles should be attached to each other and the dose should be administered into the lower half of the auricle in the internal non-hair-coated part. The basic and the lowest dose is 0.1 ml, irrespective of age, sex and weight of the animal. In non‑needle applicators which do not facilitate to administer this dose, a higher dose may be used, however such a dose must not be larger than 0.2 ml, thus a number of immunization doses in the package used will decrease accordingly. A number of doses in a pack is prescribed per an immunization dose of 0.1 ml. Animals may be primo-vaccinated from the age of 10 weeks. In regions with an unfavorable infection situation, rabbits may be primary vaccinated from 6 weeks of age with a re-vaccination over 4 weeks after primary vaccination. To maintain permanent immunity in breeding animals, regular re-vaccination every 9 months is recommended. The youngsters from immunized mothers are protected by maternal immunity that persists for approximately 4 weeks after birth. Residual amount of specific maternal antibodies may negatively influence the vaccination effect.

Size of package: 1 x 10 doses, 1 x 40 doses, 1 x 80 doses, 1 x 160 doses, 6 x 10 doses, 6 x 40 doses, 6 x 80 doses, 6 x 160 doses
Each dose represents the combination of one vial with lyophilized part MXT and one vial with liquid part RHD.
Not all pack sizes may be marketed.

For animals only. Veterinary medicinal product to be supplied only on veterinary prescription.